Exploring Advanced Weight Loss Therapies: A Comprehensive Guide

Weight Loss
Written By Glenn Cochrane
Weight Loss Therapies

Achieving and maintaining a healthy weight is a common goal for many individuals. While traditional methods like diet and exercise are essential, advancements in medical science have introduced various therapies to aid weight loss. This blog will explore several innovative treatments, including 5-Amino-1MQ, GLP-1 agonists (such as Semaglutide and Tirzepatide), growth hormone secretagogues (like Sermorelin, CJC-1295/Ipamorelin, and Tesamorelin), and the benefits of Cardarine and SLU-PP-332. It’s essential to consult with a licensed healthcare provider before starting any comprehensive weight loss program. Infinity Functional Performance is a renowned expert in functional medicine, human performance, peptide therapy, and weight loss programs, and can provide personalized guidance tailored to your needs.

 

5-Amino-1MQ: A Novel Weight Loss Agent

5-Amino-1MQ is a small molecule that has gained attention for its potential in weight management. It works by inhibiting an enzyme called nicotinamide N-methyltransferase (NNMT), which plays a role in fat cell metabolism.

How Does 5-Amino-1MQ Work?

NNMT is an enzyme found in fat cells that influences how the body stores and burns fat. By inhibiting NNMT, 5-Amino-1MQ enhances the body’s ability to break down fat cells, leading to increased fat metabolism and potential weight loss. This process can help the body use stored fat for energy more efficiently.

Benefits of 5-Amino-1MQ

• Enhanced Fat Metabolism: By blocking NNMT, 5-Amino-1MQ promotes the breakdown of fat cells, aiding in weight reduction.

• Improved Energy Levels: As the body becomes more efficient at using fat for energy, individuals may experience increased vitality and reduced fatigue.

• Potential Muscle Preservation: Some studies suggest that 5-Amino-1MQ may help maintain muscle mass during weight loss by improving energy metabolism within muscle cells.

 

GLP-1 Agonists: Semaglutide and Tirzepatide

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications initially developed to manage type 2 diabetes but have shown significant promise in promoting weight loss. Semaglutide and tirzepatide are notable examples of GLP-1 agonists.

How Do GLP-1 Agonists Work?

GLP-1 is a hormone that helps regulate blood sugar levels and appetite. GLP-1 agonists mimic this hormone, leading to increased insulin secretion, reduced glucagon release, slower gastric emptying, and a feeling of fullness. These effects contribute to reduced food intake and weight loss.

Benefits of GLP-1 Agonists

• Significant Weight Loss: Clinical trials have demonstrated substantial weight reduction in individuals treated with GLP-1 agonists.

• Improved Blood Sugar Control: By enhancing insulin secretion and sensitivity, these medications help maintain healthy blood sugar levels.

• Cardiovascular Benefits: Some studies suggest that GLP-1 agonists may reduce the risk of cardiovascular events in individuals with type 2 diabetes.

 

Growth Hormone Secretagogues: Preserving Muscle Mass During Weight Loss

During weight loss, it’s crucial to preserve muscle mass to maintain strength and metabolic health. Growth hormone secretagogues (GHS) are compounds that stimulate the body’s release of growth hormone, which plays a vital role in muscle growth and fat metabolism. Examples include Sermorelin, CJC-1295/Ipamorelin, and Tesamorelin.

How Do Growth Hormone Secretagogues Work?

GHS stimulate the pituitary gland to release growth hormone, which in turn promotes the production of insulin-like growth factor 1 (IGF-1). IGF-1 supports muscle protein synthesis and helps the body utilize fat for energy.

Benefits of Growth Hormone Secretagogues

• Muscle Preservation: By increasing growth hormone levels, GHS help maintain muscle mass during weight loss efforts.

• Enhanced Fat Metabolism: Elevated growth hormone levels can lead to increased fat breakdown, supporting weight loss.

• Improved Recovery: GHS may aid in faster recovery from exercise by promoting tissue repair and reducing muscle soreness.

 

Cardarine: Enhancing Endurance and Metabolism

Cardarine, also known as GW501516, is a compound that was initially developed to treat metabolic and cardiovascular diseases. It has gained attention for its potential to enhance endurance and promote fat loss.

How Does Cardarine Work?

Cardarine activates the peroxisome proliferator-activated receptor delta (PPAR-delta) pathway, which plays a role in regulating fat metabolism and energy expenditure.

Benefits of Cardarine

• Increased Endurance: By activating PPAR-delta, cardarine enhances the body’s ability to utilize fat for energy, improving stamina during physical activity.

• Fat Loss: Cardarine promotes the breakdown of fatty acids, aiding in weight reduction.

• Improved Lipid Profile: Some studies suggest that cardarine may help lower bad cholesterol levels and increase good cholesterol levels.

SLU-PP-332: The Exercise Mimetic

SLU-PP-332 is a novel compound that mimics the effects of exercise by activating specific metabolic pathways. It holds promise for enhancing energy expenditure and promoting fat loss.

How Does SLU-PP-332 Work?

SLU-PP-332 activates estrogen receptor-related orphan receptors (ERRs), which are involved in energy metabolism and mitochondrial function.

Benefits of SLU-PP-332

• Enhanced Energy Expenditure: By activating ERRs, SLU-PP-332 increases the body’s energy consumption, supporting weight loss efforts.

• Improved Fat Metabolism: SLU-PP-332 promotes the breakdown of fat stores, aiding in weight reduction.

Conclusion: The Importance of Medically Supervised Weight Loss Programs

 

Weight loss is a complex process that involves much more than just calorie restriction and exercise. Advancements in medical weight loss therapies, such as 5-Amino-1MQ, GLP-1 agonists (semaglutide, tirzepatide), growth hormone secretagogues (sermorelin, CJC-1295/ipamorelin, tesamorelin), cardarine, and SLU-PP-332, offer new hope for individuals struggling with stubborn weight. These medications work synergistically to enhance metabolism, improve fat loss, maintain muscle mass, and optimize overall health.

However, it is critical to undergo these treatments under the guidance of a licensed healthcare provider. Medications that affect hormone levels, metabolism, and energy pathways must be carefully managed to ensure safety, effectiveness, and optimal results. Personalized dosing, monitoring for side effects, and ongoing medical supervision are necessary for long-term success and sustainability in weight management.

At Infinity Functional Performance, we are renowned experts in functional medicine, human performance, peptide therapy, and weight loss programs. Our evidence-based, medically supervised weight loss protocols are designed to help clients achieve sustainable results while maintaining their health and well-being. Whether you are looking to improve body composition, increase energy, or enhance performance, our expert team is here to guide you every step of the way.

 

Take the Next Step Toward a Healthier You today!!!

If you are ready to experience the next generation of weight loss therapy, consult with our team at Infinity Functional Performance to develop a personalized medical weight loss program tailored to your needs. Contact us today to begin your transformation and optimize your health with cutting-edge, medically supervised weight loss solutions. 

References

  1. Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., Pirinen, E., Pulinilkunnil, T. C., Gong, F., Wang, Y. C., Cen, Y., Sauve, A. A., Asara, J. M., Peroni, O. D., Monia, B. P., Bhanot, S., Alhonen, L., Puigserver, P., & White, M. F. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258–262. https://doi.org/10.1038/nature13198

  2. Stromsdorfer, K. L., Yamaguchi, S., Yoon, M. J., Moseley, A. C., Kelly, S. C., Qi, N., & Najjar, S. M. (2016). NAMPT-mediated NAD+ biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Reports, 16(7), 1851–1860. https://doi.org/10.1016/j.celrep.2016.07.015

  3. Hong, S., Moreno-Navarrete, J. M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D., Lee, Y., Asara, J. M., Fernandez-Real, J. M., & Maratos-Flier, E. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 21(8), 887–894. https://doi.org/10.1038/nm.3882

  4. Ulanovskaya, O. A., Zuhl, A. M., & Cravatt, B. F. (2013). NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature, 491(7423), 617–620. https://doi.org/10.1038/nature11714

  5. Pissios, P. (2017). Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends in Endocrinology & Metabolism, 28(5), 340–353. https://doi.org/10.1016/j.tem.2017.02.003

  6. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

  7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

  8. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K., & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519

  9. Rubino, D., Abrahamson, M. J., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tankova, T., Wadden, T. A., & Dicker, D. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

  10. Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. (2024, December 4). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head

  11. Vittone, J. L., Blackman, M. R., Busby-Whitehead, J., Pabst, K. M., & Stewart, K. J. (1997). Effects of single nightly injections of growth hormone-releasing hormone in healthy older men. Metabolism, 46(7), 851–856. https://doi.org/10.1016/S0026-0495(97)90068-0

  12. Chapman, I. M., Hartman, M. L., Straume, M., Johnson, M. L., & Veldhuis, J. D. (1994). Enhanced sensitivity growth hormone (GH) autoregulation during prolonged GH-releasing hormone stimulation in men. Journal of Clinical Endocrinology & Metabolism, 78(5), 1205–1212. https://doi.org/10.1210/jcem.78.5.8175970

  13. Merriam, G. R., & MacMahon, M. (1992). The use of growth hormone releasing hormone in the diagnosis of growth hormone deficiency. Hormone Research, 37(Suppl 4), 41–47. https://doi.org/10.1159/000182537

  14. Walker, R. F., & Ghosh, P. (1989). Clinical aspects of growth hormone-releasing hormone therapy in children and adults. Acta Paediatrica Scandinavica Supplement, 356, 70–75. https://doi.org/10.1111/j.1651-2227.1989.tb11294.x

  15. Walker, R. F., & Ghosh, P. (1989). Clinical aspects of growth hormone-releasing hormone therapy in children and adults. Acta Paediatrica Scandinavica Supplement, 356, 70–75. https://doi.org/10.1111/j.1651-2227.1989.tb11294.x

  16. Heinrich, G., & Lairmore, T. C. (2019). Clinical review of growth hormone-releasing hormone and its analogs: Clinical and experimental aspects. Frontiers in Endocrinology, 10, 568. https://doi.org/10.3389/fendo.2019.00568

  17. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., & Castaigne, J. P. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536

  18. Smith, R. G., & Sun, Y. (2004). Developments in ghrelin biology and potential clinical relevance. Trends in Endocrinology & Metabolism, 15(9), 436–441. https://doi.org/10.1016/j.tem.2004.09.004

  19. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552

  20. Jacks, T., Sowden, J., & Smith, R. G. (1996). Ipamorelin, a novel pentapeptide, selectively stimulates the release of growth hormone in vitro and in vivo. Endocrinology, 137(2), 529–535. https://doi.org/10.1210/endo.137.2.8593799

  21. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D. P., Somero, M., Berger, D., Brown, S., & Richmond, G. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072291

  22. Guaraldi, G., & Stentarelli, C. (2006). Tesamorelin for the treatment of HIV-associated lipodystrophy. Expert Opinion on Investigational Drugs, 15(11), 1427–1439. https://doi.org/10.1517/13543784.15.11.1427

  23. Johannsson, G., Gibney, J., Wolthers, T., Leung, K. C., Ho, K. K., & Umpleby, A. M. (2005). Growth hormone-releasing hormone analog increases body protein anabolism and fat oxidation in human immunodeficiency virus-infected men. Journal of Clinical Endocrinology & Metabolism, 90(4), 1973–1979.

  24. Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., Xu, H. E., Sternbach, D. D., Kliewer, S. A., Hansen, B. C., & Willson, T. M. (2001). A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences, 98(9), 5306–5311. https://doi.org/10.1073/pnas.091021198

  25. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Mihaylova, M. M., Nelson, M. C., Zou, Y., Juguilon, H., Kang, H., Shaw, R. J., & Evans, R. M. (2008). AMPK and PPARδ agonists are exercise mimetics. Cell, 134(3), 405–415. https://doi.org/10.1016/j.cell.2008.06.051

  26. Riserus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., & Sarov-Blat, L. (2008). Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 57(2), 332–339. https://doi.org/10.2337/db07-1318

  27. Shearer, B. G., & Billin, A. N. (2007). The next generation of PPAR drugs: Do we have the tools to find better treatments? Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1771(8), 1082–1093. https://doi.org/10.1016/j.bbalip.2007.05.001

  28. TGA. (2017). 1.2. Cardarine. Therapeutic Goods Administration. https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-november-2017/12-cardarine

  29. Wang, L., Balowski, J. J., & Drenan, R. M. (2023). A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics, 387(3), 205–216. https://doi.org/10.1124/jpet.123.000001

  30. Zhang, Y., Li, Y., & Ding, S. (2023). Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chemical Biology, 18(4), 789–798. https://doi.org/10.1021/acschembio.3c00001

  31. Nasri, H. (2024). New hopes on “SLU-PP-332” as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view. Journal of Renal Endocrinology, 10, e25143. https://doi.org/10.34172/jre.2024.25143

  32. American Chemical Society. (2024). Mimicking exercise with a pill. ACS Press Release. https://www.acs.org/pressroom/presspacs/2024/march/mimicking-exercise-with-a-pill.html

  33. University of Florida News. (2023). Exercise-mimicking drug sheds weight, boosts muscle activity in mice. UF News. https://news.ufl.edu/2023/09/exercise-mimicking-drug

Glenn Cochrane https://www.ifp.life
Previous

The Best Chiropractic Practices in Gilbert, AZ: What You Need to Know
Next

Growth Hormone Secretagogues: Comparing Sermorelin, CJC-1295/Ipamorelin, and Tesamorelin